XENE Logo

Xenon Pharmaceuticals Inc. (XENE) 

NASDAQ
Market Cap
$3.05B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
767 of 774
Rank in Industry
428 of 432

Largest Insider Buys in Sector

XENE Stock Price History Chart

XENE Stock Performance

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise …

Insider Activity of Xenon Pharmaceuticals Inc.

Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $0 and sold $2.1M worth of Xenon Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $235,534 and sold $3.94M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,400 shares for transaction amount of $40,334 was made by KENNEY CHRISTOPHER JOHN (Chief Medical Officer) on 2022‑01‑21.

List of Insider Buy and Sell Transactions, Xenon Pharmaceuticals Inc.

2024-03-08Saledirector
2,092
0.0027%
$45.69$95,583-11.77%
2024-03-07SaleEVP, Strategy & Innovation
7,137
0.0095%
$46.28$330,290-11.51%
2024-03-07Saledirector
13,000
0.0173%
$46.28$601,615-11.51%
2023-12-14Saledirector
7,598
0.0103%
$41.05$311,898+1.81%
2023-12-13Saledirector
18,978
0.0257%
$39.99$758,983+5.24%
2023-08-24Saledirector
25,000
0.0391%
$38.70$967,500+5.40%
2023-06-01Saledirector
31,713
0.0485%
$38.82$1.23M+2.68%
2023-05-31Saledirector
62,526
0.0956%
$38.70$2.42M+2.88%
2023-05-30Saledirector
37,006
0.0576%
$39.28$1.45M+3.31%
2023-05-24SalePRESIDENT & CEO
31,655
0.0482%
$41.41$1.31M-3.86%
2023-03-24SaleChief Medical Officer
700
0.0011%
$35.01$24,507+10.93%
2023-03-07Saledirector
19,232
0.03%
$36.98$711,199+6.69%
2022-11-25Saledirector
1,937
0.0032%
$34.79$67,390+8.16%
2022-09-02SaleChief Financial Officer
15,355
0.0238%
$39.57$607,597-3.33%
2022-08-31SaleEVP, Strategy & Innovation
8,776
0.0134%
$38.80$340,509-2.80%
2022-08-12Sale
32,058
0.0495%
$38.29$1.23M-0.50%
2022-08-12SaleEVP, Drug Discovery
21,875
0.0341%
$38.68$846,125-0.50%
2022-03-08Saledirector
5,000
0.0092%
$30.80$154,000+17.14%
2022-03-07Saledirector
31,086
0.0572%
$30.50$948,260+18.01%
2022-03-07SaleEVP, Drug Discovery
32,853
0.0606%
$30.54$1M+18.01%

Insider Historical Profitability

26.36%
PATOU GARYdirector
4902
0.0064%
$40.0523+22.07%
GANNON STEVENdirector
2000
0.0026%
$40.0511+31.48%
BVF PARTNERS L P/IL10 percent owner
1674468
2.1963%
$40.05100<0.0001%
Hayden Michael Rdirector
161187
0.2114%
$40.0510+44.5%
AZAB MOHAMMADdirector
57561
0.0755%
$40.0551+72.32%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$284.21M8.756.6M+16.72%+$40.72M0.02
Avoro Capital Advisors Llc$243.95M7.515.67M0%+$02.92
Driehaus Capital Management LLC$186.05M5.734.32M-0.54%-$1.01M1.85
Wellington Management Company$168.84M5.23.92M-5.78%-$10.36M0.03
Capital World Investors$115.44M3.552.68M0%+$00.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.